Table 2.
Clinical Outcomes of COVID-19 Convalescent Plasma Therapy Versus Standard Care
| Variable | CPT (n = 52) | Standard Care (n = 55) | P-value |
|---|---|---|---|
| 14-day all-cause mortality, n (%) | 8 (15.38) | 47 (85.45) | < 0.001a |
| 14-day severe COVID-19 death, n (%) | 7 (13.46) | 47 (85.45) | < 0.001a |
| 28-day all-cause mortality, n (%) | 8 (15.38) | 47 (85.45) | < 0.001a |
| 28-day severe COVID-19 death, n (%) | 7 (13.46) | 47 (85.45) | < 0.001a |
| Duration of supplemental oxygen (days); median (IQR) | 5 (4–9) | 15 (9.5–18) | < 0.001b |
| Receiving mechanical ventilation, n (%) | 44/52 (84.61) | 47/55 (85.45) | 0.903a |
| Receiving high flow nasal cannula, n (%) | 16/52 (30.77) | 27/55 (49.08) | 0.053a |
| High-flow oxygen therapy; mask with bag, n (%) | 11/52 (21.15) | 39/55 (70.91) | < 0.001a |
| Low-flow oxygen cannula, n (%) | 21/52 (40.38) | 21/55 (38.18) | 0.816a |
| Length of stay (Days); median (IQR) | 10 (3–21) | 7 (1–56) | < 0.001b |
| WHO clinical progression scale < 4 on day 3 after admission | 1 (1.92) | 0 (0) | 0.486c |
| WHO clinical progression scale < 4 on day 5 after admission | 6 (11.54) | 0 (0) | 0.027c |
| WHO clinical progression scale < 4 on day 8 after admission | 23 (44.23) | 0 (0) | < 0.001a |
| WHO clinical progression scale < 4 on day 14 after admission | 38 (73.08) | 2 (7.27) | < 0.001a |
| Improvement of pneumonia from chest radiography on day 7 | 26/52 (50) | 0/55 (0) | < 0.001a |
| SpO2 after weaning of supplemental oxygen n (%) | 96 (96–99) | 89.5 (73–98) | < 0.001a |
| Number of patients success in weaning oxygen support | 44/52 (84.6) | 8/55 (14.5) | < 0.001a |
aChi-square test
bMann-Whitney U test
cFisher’s exact test
CPT convalescent plasma therapy, SpO2 oxygen saturation, IQR interquartile range, WHO World Health Organization